Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) is now available.
ResMed Inc. Chairman and CEO Michael J. Farrell has reported a series of stock option exercises and share sales conducted under a pre-arranged Rule 10b5-1 trading plan adopted in late 2024. Farrell exercised options to acquire 4,991 shares of ResMed common stock at an exercise price of $146.34 and then sold the same number of shares at a weighted average price of about $207.82.
Following these transactions, Farrell continues to hold a substantial direct stake of 466,223 ResMed shares, along with additional shares held indirectly through the Lisette and Michael Farrell Family Trust. The filing underscores ongoing insider activity at the medical device maker but does not indicate any change in his leadership role or broader strategic shift for the company.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$48.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a medical technology company specializing in devices and software for treating sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. The company focuses on digital health solutions and cloud-connected equipment used in home and clinical care settings across global markets.
Average Trading Volume: 1,342,187
Technical Sentiment Signal: Hold
Current Market Cap: A$41.45B
For a thorough assessment of RMD stock, go to TipRanks’ Stock Analysis page.